Clinical trial · Interventional
Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With Diabetes Mellitus
The Effect and Mechanism of Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With DM Who Receive Surgical Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to investigate the effect of gastrectomy on remission of type 2 diabetes in patients with gastric cancer and type 2 diabetes, to investigate the mechanism of blood glucose alteration and intestinal hormonal signaling by the reconstruction methods, and to evaluate the applicability and efficacy of Roux-en-Y gastrojejunostomy after gastrectomy in gastric cancer patients with diabetes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diabetes | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gastroduodenostomy | Procedure | — | UNRESOLVED |
| Roux-en Y gastrojejunostomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Gastroduodenostomy
- description
- Arm 1: undergo gastroduodenostomy after distal gastrectomy for gastric cancer
- interventionNames
- Procedure: Gastroduodenostomy
- type
- EXPERIMENTAL
- label
- Roux-en Y gastrojejunostomy
- description
- Arm 2: undergo Roux-en Y gastrojejunostomy after distal gastrectomy for gastric cancer
- interventionNames
- Procedure: Roux-en Y gastrojejunostomy
Primary outcomes (1)
- measure
- Blood sugar stabilization after gastrectomy
- timeFrame
- three months after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patient who are older than 20 years and younger than 80 years * Histologically confirmed gastric adenocarcinoma located lower one third of stomach * Postoperative confirmed pT1N0, pT2N0, pT1N1 * Informed consent Exclusion Criteria: * Previous history of treatment for other malignancy or inflammatory disease * Preoperative uncontrolled serious comorbidity * Vulnerable Subjects(pregnant women, children, cognitively impaired persons etc.) * Patient who experience any complications requiring reoperation following gastrectomy
References
Publications (2)
- BACKGROUNDYang J, Li C, Liu H, Gu H, Chen P, Liu B. Effects of subtotal gastrectomy and Roux-en-Y gastrojejunostomy on the clinical outcome of type 2 diabetes mellitus. J Surg Res. 2010 Nov;164(1):e67-71. doi: 10.1016/j.jss.2010.07.004. Epub 2010 Jul 30. PMID 20863527
- DERIVEDNishizaki D, Ganeko R, Hoshino N, Hida K, Obama K, Furukawa TA, Sakai Y, Watanabe N. Roux-en-Y versus Billroth-I reconstruction after distal gastrectomy for gastric cancer. Cochrane Database Syst Rev. 2021 Sep 15;9(9):CD012998. doi: 10.1002/14651858.CD012998.pub2. PMID 34523717